SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Balance, equilibrium, stability and movement concepts. Blue sphere is rolling on a yellow curved path over a blue background, creating a minimalist and abstract composition. 3d render.
Gene editing
FDA bolsters bespoke therapy framework with new draft safety guidelines
The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
April 14, 2026
 · 
2 min read
 · 
Gabrielle Masson
command failed. Business team walk in a line following faulty orders vector
Layoffs
50 employees impacted as Astellas closes Universal Cells’ Seattle office
By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology research at its South San Francisco, California, and Westborough, Massachusetts, sites.
April 14, 2026
 · 
2 min read
 · 
Angela Gabriel
Job Trends
Bonus: Q1 2026 Job Market Update
In this bonus episode, BioSpace’s Vice President of Marketing ⁠Chantal Dresner⁠ and Careers Editor ⁠Angela Gabriel⁠ take a look at Q1 job market performance and what it signals for the coming months.
April 14, 2026
 · 
1 min read
 · 
Angela Gabriel
Hand putting print screen dart and target board wooden cube on up arrows. Target of investment and business concept.
Earnings
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.
April 14, 2026
 · 
3 min read
 · 
Heather McKenzie
Globe and stack with coins. Money makes the world go round
Manufacturing
Lilly investing billions to prepare for overseas oral GLP-1 launches
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.
April 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Eli Lilly's world headquarters in Indianapolis
Mergers & acquisitions
Lilly wants to bridge cancer care gap with $300M ADC biotech buy
Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.
April 14, 2026
 · 
1 min read
 · 
Gabrielle Masson
Hands holding binoculars. Concept of search, research or strategy for business. The eyes look forward through the lens. Vector illustration for web or user interface.
Earnings
On steadier ground, pharma heads into Q1 earnings with deals top of mind
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.
April 14, 2026
 · 
5 min read
 · 
Annalee Armstrong
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.
April 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Photo collage hands body fragments palms eyesight vision espionage psychedelic concept eyes cutouts privacy violence drawing doodles.
Regulatory
FDA asks 2,200 drug developers to make trial results public, ramping up transparency push
Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the federal government’s public repository for studies, according to internal data from the FDA.
April 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS